PDT Partners LLC Buys New Position in Evolus, Inc. $EOLS

Key Points

• PDT Partners LLC has acquired a new stake in Evolus, Inc. (NASDAQ:EOLS), purchasing 60,651 shares valued at approximately $730,000.
• Insider David Moatazedi sold 16,582 shares, while Director Brady Stewart bought 30,000 shares, indicating mixed insider sentiment regarding the company's stock.
• Wall Street analysts have given Evolus a consensus rating of "Moderate Buy" with a price target averaging $21.25, despite some cutting their price targets significantly.

PDT Partners LLC purchased a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 60,651 shares of the company's stock, valued at approximately $730,000. PDT Partners LLC owned about 0.09% of Evolus as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AlphaQuest LLC purchased a new stake in Evolus in the first quarter valued at about $39,000. State of Wyoming raised its stake in Evolus by 988.1% in the first quarter. State of Wyoming now owns 3,754 shares of the company's stock valued at $45,000 after buying an additional 3,409 shares during the last quarter. IFP Advisors Inc raised its stake in Evolus by 99.0% in the first quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after buying an additional 4,691 shares during the last quarter. Rafferty Asset Management LLC acquired a new stake in shares of Evolus during the fourth quarter worth about $115,000. Finally, Man Group plc acquired a new stake in shares of Evolus during the fourth quarter worth about $121,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the transaction, the chief marketing officer owned 89,949 shares of the company's stock, valued at approximately $675,516.99. This represents a 5.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Moatazedi sold 111,323 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $10.05, for a total value of $1,118,796.15. Following the transaction, the insider directly owned 381,509 shares in the company, valued at approximately $3,834,165.45. The trade was a 22.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 133,627 shares of company stock valued at $1,325,764. Corporate insiders own 6.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on EOLS. HC Wainwright cut their price objective on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC restated a "hold" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, August 6th. BTIG Research restated a "buy" rating and issued a $18.00 price objective on shares of Evolus in a research report on Monday. Finally, Wall Street Zen cut Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Evolus has a consensus rating of "Moderate Buy" and a consensus price target of $21.25.

Evolus Trading Down 0.7%

Shares of Evolus stock traded down $0.06 during trading hours on Tuesday, hitting $7.56. The company's stock had a trading volume of 380,256 shares, compared to its average volume of 1,084,574. The firm has a fifty day moving average of $8.23 and a 200-day moving average of $10.08. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 22.00, a quick ratio of 1.86 and a current ratio of 2.27. The stock has a market cap of $488.66 million, a price-to-earnings ratio of -7.71 and a beta of 1.07.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.